"The School aims to enhance the way we use technology in research, food security, microbiology, ecosystem biology, sustainability and many other related areas. The School is dedicated to providing the ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared ...

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim ...

GS-1427 is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

Lupin shares in focus after FDA approval for generic HIV tablets Lupin Share Price: Indian pharmaceutical giant Lupin gained US FDA approval for its generic version of Gilead Sciences' HIV drug ...

Polaris Global Equity Strategy highlighted stocks like Gilead Sciences, Inc. (NASDAQ:GILD), in the third quarter 2024 investor letter. Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lupin Share Price: Indian pharmaceutical giant Lupin gained US FDA approval for its generic version of Gilead Sciences' HIV drug Descovy. This win grants Lupin 180 days of shared exclusivity in the US ...